

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 45 to 60 of 2019**

Statements of Principles Nos. 45 to 60 of 2019 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 26 April 2019.

The Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). The day of commencement as specified in each of the Instruments is 27 May 2019. In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

30 April 2019

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Code** |
| **REVOCATIONS** |
|  |  |  |  |
| 45 & 46/2019 | rapidly progressive crescentic glomerulonephritis | 27/05/2019 | Nil |
|  |  |  |  |
| 47 & 48/2019 | posterior adventitial heel bursitis | 27/05/2019 | Nil |
|  |  |  |  |
| 49 & 50/2019 | poisoning from plants or fungi | 27/05/2019 | Nil |
|  |  |  |  |
| 51 & 52/2019 | rheumatic heart disease | 27/05/2019 | I05, I06, I07, I08 or I09 |
|  |  |  |  |
| 53 & 54/2019 | acute rheumatic fever | 27/05/2019 | I00, I01 or I02 |
|  |  |  |  |
| 55 & 56/2019 | dislocation of a joint and subluxation of a joint | 27/05/2019 | Nil |
|  |  |  |  |
| 57 & 58/2019 | joint instability | 27/05/2019 | M22.0, M22.1, M23.5, M24.2, M24.4, M25.3, M43.3, M43.4, M43.5, M53.2 or T84.0 |
|  |  |  |  |
| 59 & 60/2019 | gout | 27/05/2019 | M10 |
|  |  |  |  |

**Note:**

The investigation concerning 'heel bursitis' has resulted in the determination of Statements of Principles concerning **posterior adventitial heel bursitis**.

The investigation concerning 'poisoning and toxic reaction from plants and fungi' has resulted in the determination of Statements of Principles concerning **poisoning from plants or fungi**.

The investigation concerning 'dislocation' has resulted in the determination of Statements of Principles concerning **dislocation of a joint and subluxation of a joint**.

| **SUMMARY OF CHANGES** |
| --- |
| 45 & 46/2019 | rapidly progressive crescentic glomerulonephritis | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *rapidly progressive crescentic glomerulonephritis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 45/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'rapidly progressive crescentic glomerulonephritis' in subsection 7(2);
* revising the factor in subsection 9(1) concerning 'an infection';
* revising the factor in subsection 9(2) concerning 'an autoimmune disorder';
* new factor in subsection 9(3) concerning 'infiltration of the kidneys due to a disorder';
* new factor in subsection 9(4) concerning 'a renal disorder';
* revising the factor in subsection 9(6) concerning 'a drug or a drug from a class of drugs';
* revising the factor in subsection 9(7) concerning 'acute volatile substance intoxication';
* revising the factor in subsection 9(8) concerning 'an organic solvent';
* new definitions of 'MRCA', 'organic solvent', 'specified list of autoimmune disorders', 'specified list of drugs', specified list of infections', 'specified list of infiltrative disorders', 'specified list of renal disorders' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'acute volatile substance intoxication' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a specified drug', 'a specified immune or autoimmune disorder', 'a specified infection' and 'organic solvents'.

***For BoP SoP*** ***(Instrument No. 46/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'rapidly progressive crescentic glomerulonephritis' in subsection 7(2);
* revising the factor in subsection 9(1) concerning 'an infection';
* revising the factor in subsection 9(2) concerning 'an autoimmune disorder';
* new factor in subsection 9(3) concerning 'infiltration of the kidneys due to a disorder';
* new factor in subsection 9(4) concerning 'a renal disorder';
* revising the factor in subsection 9(6) concerning 'a drug from the specified list of drugs';
* new definitions of 'MRCA', 'specified list of autoimmune disorders', 'specified list of drugs', specified list of infections', 'specified list of infiltrative disorders', 'specified list of renal disorders' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a specified drug', 'a specified immune or autoimmune disorder' and 'a specified infection'.

**The determining of these Instruments finalises the investigation in relation to *rapidly progressive crescentic glomerulonephritis* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 47 & 48/2019 | posterior adventitial heel bursitis | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *heel bursitis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH & BoP SoPs*** ***(Instrument Nos. 47 & 48/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'posterior adventitial heel bursitis';
* new definition of 'posterior adventitial heel bursitis' in subsection 7(2);
* revising the factors in subsections 9(1) & 9(3) concerning 'wearing footwear that causes friction or pressure';
* new factors in subsections 9(2) & 9(4) concerning 'having a Haglund deformity';
* new definitions of 'Haglund deformity', 'MRCA', 'plantar calcaneal bursitis' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 – Dictionary.

**The determining of these Instruments finalises the investigation in relation to *heel bursitis* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 49 & 50/2019 | poisoning from plants or fungi | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 8 May 2018 concerning *poisoning and toxic reaction from plants and fungi* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH & BoP SoPs*** ***(Instrument Nos. 49 & 50/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'poisoning from plants or fungi';
* new definition of 'poisoning from plants or fungi' in subsection 7(2);
* revising the factor in subsection 9(1) concerning 'ingesting, inhaling, injecting or having cutaneous, intradermal, mucosal or ocular exposure to a toxin';
* revising the factor in subsection 9(2) concerning 'consuming milk, milk products, eggs or meat';
* new factor in subsection 9(3) concerning 'consuming honey';
* new factor in subsection 9(4) concerning 'ingesting, inhaling, injecting or having cutaneous, intradermal, mucosal or ocular exposure to a plant', for poisoning manifesting as delayed hepatotoxicity, delayed nephrotoxicity or delayed neurotoxicity only;
* new factor in subsection 9(5) concerning 'consuming milk, milk products, eggs or meat', for poisoning manifesting as delayed hepatotoxicity, delayed neurotoxicity or delayed thyrotoxicity only;
* new factor in subsection 9(6) concerning 'consuming honey', for poisoning manifesting as delayed hepatotoxicity only;
* deleting the factor concerning 'inhaling, ingesting or having cutaneous contact with a plant containing a pyrrolizidine alkaloid', as it is covered by the factor in subsection 9(4) concerning 'ingesting, inhaling, injecting or having cutaneous, intradermal, mucosal or ocular exposure to a plant';
* new definitions of 'MRCA', 'specified list of plant toxins', 'Specified List 1 of plants', 'Specified List 2 of plants', 'Specified List 3 of plants' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a plant containing a pyrrolizidine alkaloid' and 'poison'.

**The determining of these Instruments finalises the investigation in relation to *poisoning and toxic reaction from plants and fungi* as advertised in the Government Notices Gazette of 8 May 2018.** |
| 51 & 52/2019 | rheumatic heart disease | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 8 May 2018 concerning *rheumatic heart disease* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH & BoP SoPs*** ***(Instrument Nos. 51 & 52/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'rheumatic heart disease' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(4) concerning 'acute rheumatic fever';
* new factors in subsections 9(3) & 9(6) concerning 'crowded living or working conditions';
* revising the factor in subsection 9(5) concerning 'group A beta-haemolytic streptococcal infection';
* revising the factor in subsection 9(7) concerning 'being pregnant';
* new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'group A beta-haemolytic streptococcal infection'.

**The determining of these Instruments finalises the investigation in relation rheumatic heart diseaseas advertised in the Government Notices Gazette of 8 May 2018.**  |
| 53 & 54/2019 | acute rheumatic fever | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 8 May 2018 concerning *acute rheumatic fever* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 53/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'acute rheumatic fever' in subsection 7(2);
* new factor in subsection 9(2) concerning 'a group A beta-haemolytic streptococcal infection of the skin or the pharynx', for acute rheumatic fever manifesting as isolated chorea or as indolent subclinical carditis only;
* new factor in subsection 9(3) concerning 'a group C or G streptococcal infection of the pharynx';
* revising the factor in subsection 9(4) concerning 'crowded living or working conditions';
* new factor in subsection 9(5) concerning 'dental caries';
* new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'group A beta-haemolytic streptococcal infection'.

***For BoP SoP*** ***(Instrument No. 54/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'acute rheumatic fever' in subsection 7(2);
* new factor in subsection 9(2) concerning 'a group A beta-haemolytic streptococcal infection of the pharynx', for acute rheumatic fever manifesting as isolated chorea or as indolent subclinical carditis only;
* revising the factor in subsection 9(3) concerning 'crowded living or working conditions';
* new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'group A beta-haemolytic streptococcal infection'.

**The determining of these Instruments finalises the investigation in relation to *acute rheumatic fever* as advertised in the Government Notices Gazette of 8 May 2018.** |
| 55 & 56/2019 | dislocation of a joint and subluxation of a joint | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *dislocation* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 55/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'dislocation of a joint and subluxation of a joint';
* new definition of 'dislocation of a joint and subluxation of a joint' in subsection 7(2);
* removing the reference to 'ICD-10-AM code';
* revising the factor in subsection 9(1) concerning 'physical trauma to the affected joint';
* revising the factor in subsection 9(2) concerning 'damage to a soft tissue structure';
* revising the factor in subsection 9(3) concerning 'fracture, avulsion or bony abnormality involving the articulating surfaces';
* revising the factor in subsection 9(4) concerning 'disease process as specified affecting the normal structural or functional relationship between the articulating surfaces of the affected joint';
* new factor in subsection 9(5) concerning 'being pregnant';
* revising the factor in subsection 9(6) concerning 'undertaking an activity or undergoing a medical procedure that involves wide opening of the mouth', for dislocation of a temporomandibular joint or subluxation of a temporomandibular joint only;
* new factor in subsection 9(7) concerning 'being obese', for dislocation of a patellofemoral joint only;
* new factor in subsection 9(8) concerning 'being severely obese', for dislocation of a tibiofemoral joint or subluxation of a tibiofemoral joint only;
* new factor in subsection 9(9)(a) concerning 'being obese', for dislocation of a total hip joint prosthesis only;
* new factor in subsection 9(9)(b) concerning 'lumbar spondylosis, lumbar intervertebral disc prolapse, lumbar spondylolisthesis, lumbar spinal stenosis or lumbar spinal fusion', for dislocation of a total hip joint prosthesis only;
* new factor in subsection 9(10) concerning 'morbid obesity', for dislocation of a total knee joint prosthesis only;
* deleting the factors concerning 'having an inflammatory or infectious condition involving the ear, nose or throat' and 'having undergone a surgical procedure involving the head or neck' as these are now covered by the factor in subsection 9(4) concerning 'disease process as specified affecting the normal structural or functional relationship between the articulating surfaces of the affected joint';
* deleting the factors concerning 'tracheal intubation' and 'intravenous sedation' as these are now covered by the factor in subsection 9(6) concerning 'undertaking an activity or undergoing a medical procedure that involves wide opening of the mouth', for dislocation of a temporomandibular joint or subluxation of a temporomandibular joint only;
* deleting the factor concerning 'laxity of the joint capsule or a stabilising ligament of the affected joint';
* deleting the factor concerning 'biomechanical abnormality';
* new definitions of 'being obese', 'being severely obese', 'BMI', 'disease process as specified', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'relevant service' and 'soft tissue structure as specified' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a biomechanical abnormality involving the affected joint', 'a disease process affecting the normal structural or functional relationship between the articulating surfaces of the affected joint', 'an activity that involves wide opening of the mouth', 'neuropathic arthropathy' and 'physical trauma to the affected joint'.

***For BoP SoP*** ***(Instrument No. 56/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'dislocation of a joint and subluxation of a joint';
* new definition of 'dislocation of a joint and subluxation of a joint' in subsection 7(2);
* removing the reference to 'ICD-10-AM code';
* revising the factor in subsection 9(1) concerning 'physical trauma to the affected joint';
* revising the factor in subsection 9(2) concerning 'damage to a soft tissue structure';
* revising the factor in subsection 9(3) concerning 'fracture, avulsion or bony abnormality involving the articulating surfaces';
* revising the factor in subsection 9(4) concerning 'disease process as specified affecting the normal structural or functional relationship between the articulating surfaces of the affected joint';
* revising the factor in subsection 9(5) concerning 'a medical procedure that involves wide opening of the mouth', for dislocation of a temporomandibular joint or subluxation of a temporomandibular joint only;
* new factor in subsection 9(6) concerning 'being severely obese', for dislocation of a tibiofemoral joint or subluxation of a tibiofemoral joint only;
* new factor in subsection 9(7)(a) concerning 'being obese', for dislocation of a total hip joint prosthesis only;
* new factor in subsection 9(7)(b) concerning 'lumbar spondylosis, lumbar intervertebral disc prolapse, lumbar spondylolisthesis, lumbar spinal stenosis or lumbar spinal fusion', for dislocation of a total hip joint prosthesis only;
* deleting the factors concerning 'having an inflammatory or infectious condition involving the ear, nose or throat' and 'having undergone a surgical procedure involving the head or neck' as these are now covered by the factor in subsection 9(4) concerning 'disease process as specified affecting the normal structural or functional relationship between the articulating surfaces of the affected joint';
* deleting the factors concerning 'tracheal intubation' and 'intravenous sedation' as these are now covered by the factor in subsection 9(5) concerning 'undertaking an activity or undergoing a medical procedure that involves wide opening of the mouth', for dislocation of a temporomandibular joint or subluxation of a temporomandibular joint only;
* deleting the factor concerning 'laxity of the joint capsule or a stabilising ligament of the affected joint';
* deleting the factor concerning 'biomechanical abnormality';
* new definitions of 'being obese', 'BMI', 'disease process as specified', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'relevant service' and 'soft tissue structure as specified' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a biomechanical abnormality involving the affected joint', 'a disease process affecting the normal structural or functional relationship between the articulating surfaces of the affected joint', 'an activity that involves wide opening of the mouth', 'neuropathic arthropathy' and 'physical trauma to the affected joint'.

On 11 October 2018, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors relating to laxity of the joint capsule or a stabilising ligament and biomechanical abnormality. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. Minor typographical changes were made to the proposed Instruments following this consultation process.**The determining of these Instruments finalises the investigation in relation to *dislocation* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 57 & 58/2019 | joint instability  | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *joint instability* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 57/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'joint instability' in subsection 7(2);
* revising ICD-10-AM codes for 'joint instability' in subsection 7(3);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* new factors in subsections 9(1) & 9(14) concerning 'physical trauma';
* new factor in subsection 9(2) concerning 'dislocation or subluxation', for clinical onset only;
* new factor in subsection 9(3) concerning 'sprain', for clinical onset only;
* revising the factors in subsections 9(4) & 9(15) concerning 'damage to a soft tissue structure as specified';
* revising the factors in subsections 9(5) & 9(16) concerning 'fracture or bony abnormality involving the articulating surfaces';
* revising the factors in subsections 9(6) & 9(17) concerning 'disease process as specified', by the inclusion of a note;
* new factors in subsections 9(7) & 9(18) concerning 'being pregnant';
* new factors in subsections 9(8) & 9(19) concerning 'undertaking an activity or undergoing a medical procedure that involves wide opening of the mouth', for temporomandibular joint instability only;
* new factors in subsections 9(9) & 9(20) concerning 'having lumbar spondylosis, lumbar intervertebral disc prolapse, lumbar spondylolisthesis, lumbar spinal stenosis or lumbar spinal fusion', for total hip prosthesis joint instability only;
* new factors in subsections 9(10) & 9(21) concerning 'being obese', for total hip joint prosthesis joint instability only;
* new factors in subsections 9(11) & 9(22) concerning 'being severely obese', for tibiofemoral joint instability only;
* new factors in subsections 9(12) & 9(23) concerning 'morbid obesity', for total knee joint prosthesis joint instability only;
* new factors in subsections 9(13) & 9(24) concerning 'local glucocorticoid injections for epicondylitis', for elbow joint instability only;
* deleting the factors concerning 'laxity of the joint capsule or a stabilising ligament of the affected joint' and 'a biomechanical abnormality involving the affected joint';
* new definitions of 'being obese', 'being severely obese', 'BMI', 'disease process as specified', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'a biomechanical abnormality involving the affected joint', 'a disease process affecting the normal structural or functional relationship between the articulating surfaces of the affected joint' and 'neuropathic arthropathy'.

***For BoP SoP*** ***(Instrument No. 58/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'joint instability' in subsection 7(2);
* revising ICD-10-AM codes for 'joint instability' in subsection 7(3);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* new factors in subsections 9(1) & 9(11) concerning 'physical trauma';
* new factor in subsection 9(2) concerning 'dislocation or subluxation', for clinical onset only;
* new factor in subsection 9(3) concerning 'sprain', for clinical onset only;
* revising the factors in subsections 9(4) & 9(12) concerning 'damage to a soft tissue structure as specified';
* revising the factors in subsections 9(5) & 9(13) concerning 'fracture or bony abnormality involving the articulating surfaces';
* revising the factors in subsections 9(6) & 9(14) concerning 'disease process as specified', by the inclusion of a note;
* new factors in subsections 9(7) & 9(15) concerning 'undertaking an activity or undergoing a medical procedure that involves wide opening of the mouth', for temporomandibular joint instability only;
* new factors in subsections 9(8) & 9(16) concerning 'having lumbar spondylosis, lumbar intervertebral disc prolapse, lumbar spondylolisthesis, lumbar spinal stenosis or lumbar spinal fusion', for total hip prosthesis joint instability only;
* new factors in subsections 9(9) & 9(17) concerning 'being obese', for total hip joint prosthesis joint instability only;
* new factors in subsections 9(10) & 9(18) concerning 'morbid obesity', for tibiofemoral joint instability only;
* deleting factors concerning 'laxity of the joint capsule or a stabilising ligament of the affected joint' and 'a biomechanical abnormality involving the affected joint';
* new definitions of 'being obese', 'BMI', 'disease process as specified', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'a biomechanical abnormality involving the affected joint', 'a disease process affecting the normal structural or functional relationship between the articulating surfaces of the affected joint' and 'neuropathic arthropathy'.

On 14 December 2018, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors relating to laxity of the joint capsule or a stabilising ligament of the affected joint and a biomechanical abnormality involving the affected joint. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. Minor typographical changes were made to the proposed Instruments following this consultation process.**The determining of these Instruments finalises the investigation in relation to *joint instability* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 59 & 60/2019 | gout | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *gout* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 59/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'gout' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(26) concerning 'haematological disorders';
* new factors in subsections 9(2) & 9(27) concerning 'antihypertensive drugs';
* new factors in subsections 9(3) & 9(28) concerning 'low-dose aspirin';
* revising the factors in subsections 9(4) & 9(29) concerning 'a drug or a drug from a class of drugs';
* revising the factors in subsections 9(5) & 9(30) concerning 'undergoing chemotherapy for a malignant neoplasm';
* revising the factors in subsections 9(6) & 9(31) concerning 'being overweight', by the inclusion of a note;
* revising the factors in subsections 9(7) & 9(32) concerning 'alcohol';
* revising the factors in subsections 9(8) & 9(33) concerning 'alcohol';
* revising the factors in subsections 9(9) & 9(34) concerning 'meat or offal';
* revising the factors in subsections 9(10) & 9(35) concerning 'meat or offal';
* revising the factors in subsections 9(11) & 9(36) concerning 'seafood';
* revising the factors in subsections 9(12) & 9(37) concerning 'seafood';
* revising the factors in subsections 9(13) & 9(38) concerning 'fruit juice; or non-diet soft drink or other manufactured drink sweetened with fructose or sucrose';
* revising the factors in subsections 9(14) & 9(39) concerning 'fasting';
* new factors in subsections 9(15) & 9(40) concerning 'being dehydrated';
* revising the factors in subsections 9(17) & 9(42) concerning 'solid organ transplant, stem cell transplant or bone marrow transplant';
* new factors in subsections 9(18) & 9(43) concerning 'surgery';
* new factors in subsections 9(20) & 9(45) concerning 'psoriasis or psoriatic arthritis';
* revising the factors in subsections 9(21) & 9(46) concerning 'chronic kidney disease';
* revising the factors in subsections 9(23) & 9(48) concerning 'dyslipidaemia', by inclusion of a note;
* new factors in subsections 9(24) & 9(49) concerning 'total parenteral nutrition';
* new factors in subsections 9(25) & 9(50) concerning 'trauma to the affected joint or tissue';
* deleting the factors concerning 'type 2 diabetes mellitus';
* new definitions of 'abnormality of kidney structure or function', 'being dehydrated', 'BMI', 'chronic kidney disease', 'MRCA', 'specified list of antihypertensive drugs', specified list of haematological disorders', 'Specified List 1 of drugs', 'Specified List 2 of drugs' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'being overweight', 'dyslipidaemia' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a specified haematological disorder', 'alcohol', 'being treated with a drug or a drug from a class of drugs as specified', 'chronic renal failure' and 'red meat'.

***For BoP SoP*** ***(Instrument No. 60/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'gout' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(22) concerning 'haematological disorders';
* new factors in subsections 9(2) & 9(23) concerning 'antihypertensive drugs';
* new factors in subsections 9(3) & 9(24) concerning 'low-dose aspirin';
* revising the factors in subsections 9(4) & 9(25) concerning 'a drug or a drug from a class of drugs';
* revising the factors in subsections 9(5) & 9(26) concerning 'undergoing chemotherapy for a malignant neoplasm';
* revising the factors in subsections 9(6) & 9(27) concerning 'being overweight';
* revising the factors in subsections 9(7) & 9(28) concerning 'alcohol';
* revising the factors in subsections 9(8) & 9(29) concerning 'alcohol';
* revising the factors in subsections 9(9) & 9(30) concerning 'meat or offal';
* revising the factors in subsections 9(10) & 9(31) concerning 'meat or offal';
* revising the factors in subsections 9(11) & 9(32) concerning 'seafood';
* revising the factors in subsections 9(12) & 9(33) concerning 'seafood';
* revising the factors in subsections 9(13) & 9(34) concerning 'fruit juice; or non-diet soft drink or other manufactured drink sweetened with fructose or sucrose';
* revising the factors in subsections 9(14) & 9(35) concerning 'fasting';
* new factors in subsections 9(15) & 9(36) concerning 'being dehydrated';
* revising the factors in subsections 9(17) & 9(38) concerning 'solid organ transplant, stem cell transplant or bone marrow transplant';
* new factors in subsections 9(18) & 9(39) concerning 'surgery';
* new factors in subsections 9(20) & 9(41) concerning 'psoriasis or psoriatic arthritis';
* revising the factors in subsections 9(21) & 9(42) concerning 'chronic kidney disease';
* new definitions of 'abnormality of kidney structure or function', 'being dehydrated', 'being overweight', 'BMI', 'chronic kidney disease', 'MRCA', 'specified list of antihypertensive drugs', specified list of haematological disorders', 'Specified List 1 of drugs', 'Specified List 2 of drugs' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a specified haematological disorder', 'alcohol', 'being obese', 'being treated with a drug or a drug from a class of drugs as specified', 'chronic renal failure' and 'red meat'.

On 14 December 2018, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors from the Reasonable Hypothesis Statement of Principles relating to type 2 diabetes mellitus. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. No changes were made to the proposed Instruments following this consultation process.**The determining of these Instruments finalises the investigation in relation to *gout* as advertised in the Government Notices Gazette of 14 November 2017.** |